Prestige BioPharma Limited (KRX:950210)

South Korea flag South Korea · Delayed Price · Currency is KRW
14,460
+80 (0.56%)
Apr 16, 2025, 3:30 PM KST
76.34%
Market Cap 172.84B
Revenue (ttm) 5.87B
Net Income (ttm) -29.85B
Shares Out 12.02M
EPS (ttm) -496.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 103,774
Average Volume 150,483
Open 14,540
Previous Close 14,380
Day's Range 14,390 - 14,910
52-Week Range 7,610 - 20,900
Beta 1.13
RSI 55.23
Earnings Date May 30, 2025

About Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 54
Stock Exchange Korea Stock Exchange
Ticker Symbol 950210
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.